2019 Ryan White HIV/AIDS Program CLINICAL CONFERENCE

Leronlimab (PRO 140) in people with drug-resistant HIV

• Treatment-experienced people with multi-drug resistant R5-tropic HIV • Randomized to receive PRO140 + baseline ART vs. placebo + baseline ART • All participants then start open label PRO140 + optimized background regimen Results: ▫ >0.5 log reduction in VL after single injection: 64% in PRO 140 treated group vs. 23% in placebo group ▫ Week 25: 81% of participants with VL <50 •

DhodyK,ASM2019,AbstractAA-713

Slide37of 44FromRTGandhi, MD atNewOrleans, LA,December 4-7, 2019, Ryan WhiteHIV/AIDS ProgramCLINICAL CONFERENCE, IAS  USA.

Broadly Neutralizing Antibodies against HIV

Slide courtesyofPablo Tebas,MD

Slide38of 44FromRTGandhi, MD atNewOrleans, LA,December 4-7, 2019, Ryan WhiteHIV/AIDS ProgramCLINICAL CONFERENCE, IAS  USA.

Combination of 2 Antibodies Maintained HIV suppression in Absence of ART in Some People

(n=15)

• 15 participants received a combination of 2 bNAb and then stopped ART after first dose • Combination of 2 bNAbs maintained viral suppression for median of 15 wk after last dose • 2 participants maintained HIV suppression > 24 weeks

100

NobNAb

p<0.0001

3BNC117

75

3BNC117+ 10-1074

50

25

%Below200 copies/ml

0 5 10 15 20 25 30 0

WeeksofATI

Will need to combine antibodies with multiple specificities

Mendoza etal,Nature (2018)561;479-484

Slide39of 44FromRTGandhi, MD atNewOrleans, LA,December 4-7, 2019, Ryan WhiteHIV/AIDS ProgramCLINICAL CONFERENCE, IAS  USA.